Stiff Person Syndrome with Subacute Onset, Rapid Progression, and Marked Functional Impairment
This protocol addresses Stiff Person Syndrome presenting in a specific, clinically urgent pattern: symptoms that develop over days to weeks, progress rapidly, and produce significant functional loss — a scenario that demands prompt, structured intervention.
Clinical Scenario
Subacute onset with rapid clinical progression is a recognised and particularly demanding presentation of Stiff Person Syndrome. It is associated with marked functional impairment and warrants immediate evaluation and an expedited management approach.
Treatment Approach
Management in this setting combines symptomatic treatment with first-line immunotherapy; evaluation and treatment of any identified underlying cause is also an integral part of the approach. The complete regimen, sequencing, and additional components are detailed in the full protocol.
Treatment Goals
- Reduction of stiffness and spasms
- Improved performance on timed functional activities
- Decrease in relevant antibody titres where applicable
References
DOI: 10.1002/mdc3.12629
- Subacute presentations, often rapidly progressive, are particularly seen in PERM.
- Subacute onset, Rapid progression, Marked impairment
- Midazolam / propofol i.v.
- In the case of an underlying tumour, its identification and removal or treatment is of course of paramount importance.
- PLEX +/ IVIG +/ MP i.v. plus MP p.o.
- Such an assessment may for example involve the degree and distribution of stiffness, the response to a repeated standard stimulus such as a loud clap or a cold spray to the foot sole, and appropriate timed activities like walking a predefined distance, taking a flight of stairs or, in a patient with a stiff arm, the nine-hole-peg test.
- Neuronal surface antibodies can provide additional, supportive information, as for example GlyR- and DPPX-antibody titres tend to correlate with disease severity, and their decrease may herald the immunotherapy being effective.